> SkyePharma officials say they have no idea why the company's stock has dropped to near record lows. The UK developer has been planning to spin off its injectables unit and license out Flutiform outside the U.S. And a spokesperson insists those plans are all on track. Report
> GlaxoSmithKline says it will pay $70 million to settle government claims that the company inflated its prices for public health programs. Report
> Symbollon Pharmaceuticals says it plans to wrap up enrolling patients in its Phase III trial of the pain therapy IoGen by the end of this year. Results are expected in mid-2007. The trial focuses on women with moderate to severe periodic breast pain associated with fibrocystic breast disease. Article
> Array BioPharma has raised $14 million from a sale-leaseback deal on its facilities. Report
> The FDA has warned three large pharmacies to stop making large batches of brand name drugs on their own. Report
> Cognia is expanding its tech operations in the UK. Release
And Finally… A new study that shows babies under six months of age are significantly more likely to be obese than those born 20 years ago. Report (WSJ sub. req.)